Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens

(2020) Rui Zhang et al.   BIOMATERIALS

A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

(2020) Masao Nakajima et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients

(2020) H. Daiko et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

(2019) G. Travis Clifton et al.   CLINICAL IMMUNOLOGY

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors

(2019) Fangjun Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

(2019) Tommy A. Brown et al.   Cancer Medicine

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

(2019) Marit M. Melssen et al.   Journal for ImmunoTherapy of Cancer

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial

(2019) Yasuhiro Shimizu et al.   CANCER SCIENCE

TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy

(2019) Zhaoxu Xu et al.   LIFE SCIENCES

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

(2018) Raghav Sundar et al.   BMC CANCER

Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer

(2018) Wataru Obara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer

(2018) Junichiro Kawamura et al.   CANCER SCIENCE

Narrowing the diversification of supramolecular assemblies by preorganization

(2018) Zhongyan Wang et al.   CHEMICAL COMMUNICATIONS

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence – Implications for vaccine trial design

(2018) O. Jackson Doreen et al.   CLINICAL IMMUNOLOGY

Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer

(2018) Kosei Hasegawa et al.   JOURNAL OF IMMUNOTHERAPY

A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors

(2018) Yasuki Hijikata et al.   PLoS One

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

(2018) Sumiyuki Nishida et al.   Cancer Immunology Research

Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer

(2018) Sri Krishna et al.   CANCER RESEARCH

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

(2018) Julie Westerlin Kjeldsen et al.   Frontiers in Immunology

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

(2018) Chiara Camisaschi et al.   BMC CANCER

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

(2018) Akihiro Tsuboi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Actively personalized vaccination trial for newly diagnosed glioblastoma

(2018) Norbert Hilf et al.   NATURE

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

(2018) Yoshitaka Narita et al.   NEURO-ONCOLOGY

Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis

(2018) Basit Jabbar et al.   Frontiers in Immunology

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors

(2017) Arlene E. Garcia-Soto et al.   GYNECOLOGIC ONCOLOGY

Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines

(2017) Felix Rueda et al.   IMMUNOBIOLOGY

Multiple therapeutic peptide vaccines for patients with advanced gastric cancer

(2017) Yoshiyuki Fujiwara et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice

(2017) Atefeh Arab et al.   JOURNAL OF DRUG TARGETING

Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

(2017) Yoshitaro Shindo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Neoantigen prediction and the need for validation

(2017) Antonella Vitiello et al.   NATURE BIOTECHNOLOGY

Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma

(2017) Jie Shen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity

(2017) Geng Liu et al.   GigaScience

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

(2017) Nobuhiro Tsuchiya et al.   OncoImmunology

A Powerful CD8+T-Cell Stimulating D-Tetra-Peptide Hydrogel as a Very Promising Vaccine Adjuvant

(2016) Zichao Luo et al.   ADVANCED MATERIALS

A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder

(2016) W Obara et al.   ANNALS OF ONCOLOGY

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

(2016) E. A. Mittendorf et al.   ANNALS OF ONCOLOGY

Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma

(2016) Wataru Obara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion

(2016) Yosuke Kano et al.   CANCER SCIENCE

Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study

(2016) Nobuaki Suzuki et al.   CANCER SCIENCE

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

(2016) R. Rampling et al.   CLINICAL CANCER RESEARCH

Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

(2016) Mutsunori Murahashi et al.   CLINICAL IMMUNOLOGY

A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

(2016) Kazuhiro Yoshimura et al.   EUROPEAN UROLOGY

Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients

(2016) Motoki Miyazawa et al.   INTERNATIONAL JOURNAL OF CANCER

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

(2016) Yusuke Oji et al.   INTERNATIONAL JOURNAL OF CANCER

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

(2016) MORENA ANTONILLI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

(2016) Brian I Rini et al.   LANCET ONCOLOGY

A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients

(2016) Catherine Gallou et al.   Oncotarget

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

(2016) Elizabeth A. Mittendorf et al.   Oncotarget

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

(2016) Koichi Takayama et al.   Journal of Immunology Research

Peptide vaccines in breast cancer: The immunological basis for clinical response

(2015) Lívia de Paula Peres et al.   BIOTECHNOLOGY ADVANCES

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

(2015) Deepa K. Krishnadas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

(2015) M. Noguchi et al.   CLINICAL CANCER RESEARCH

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial

(2015) A. Legat et al.   CLINICAL CANCER RESEARCH

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)

(2015) David H. Lawson et al.   JOURNAL OF CLINICAL ONCOLOGY

In situ Delivery of Tumor Antigen– and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells

(2015) Martine A. Boks et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children

(2015) Akihisa Sawada et al.   PEDIATRIC BLOOD & CANCER

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

(2015) Pierpaolo Correale et al.   OncoImmunology

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

(2014) E. A. Mittendorf et al.   ANNALS OF ONCOLOGY

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS

(2014) Y. Yoshitake et al.   CLINICAL CANCER RESEARCH

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

(2014) Hisae Iinuma et al.   Journal of Translational Medicine

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

(2014) Athanasios Kotsakis et al.   LUNG CANCER

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

The immune epitope database (IEDB) 3.0

(2014) Randi Vita et al.   NUCLEIC ACIDS RESEARCH

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

(2013) Hiroyuki Suzuki et al.   Journal of Translational Medicine

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients

(2013) Ryuji Okuyama et al.   OncoImmunology

Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay

(2012) Yasuto Akiyama et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

(2012) D. T. Le et al.   CANCER RESEARCH

TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization

(2012) Kendra Smyth et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Liposomes and nanotechnology in drug development: focus on oncotargets

(2012) Tomohiro Kozako et al.   International Journal of Nanomedicine

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

(2012) Koji Kono et al.   Journal of Translational Medicine

A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens

(2011) Ursula J. E. Seidel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma

(2011) Ulrike Gerdemann et al.   MOLECULAR THERAPY

Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles

(2011) Seyed Amir Jalali et al.   Nanomedicine-Nanotechnology Biology and Medicine

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

(2010) Michael J. Ciesielski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PR1 vaccination in myeloid malignancies

(2008) Katayoun Rezvani   Expert Review of Vaccines